Isis Announces That OGX-011 Has Shown Overall Survival Advantage In Prostate Cancer Compared To Standard Therapy In A Randomized Phase 2 Study
Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) announced that OncoGenex Pharmaceuticals, Inc. provided positive survival results from a randomized Phase 2 clinical trial of OGX-011 in combination with docetaxel and prednisone ("the OGX-011 arm") compared to docetaxel and prednisone alone ("the control arm") for first-line treatment of metastatic castrate resistant prostate cancer. The current 10.
Source: www.medicalnewstoday.com

Sucampo Completes Enrollment In Phase 3 Pivotal Studies Of Oral Lubiprostone To Treat Opioid-Induced Bowel Dysfunction
Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) today announced that it has completed enrollment and initial dosing of patients in two pivotal phase 3 trials of lubiprostone for the treatment of Opioid-Induced Bowel Dysfunction (OBD). "If lubiprostone is successful in Phase 3, we believe that it could represent a breakthrough in the treatment of patients suffering from OBD," said Ryuji Ueno, M.D., Ph.D., Ph.D.
Source: www.medicalnewstoday.com

Media Examine Opposition To Proposed HHS Conscience Rule
The Florida Times-Union on Wednesday examined reactions in Florida to the proposed HHS conscience rule, which would permit health care providers who receive federal grants to opt out of medical care based on their moral or religious beliefs.
Source: www.medicalnewstoday.com

Evotec Announces Three-Year Drug Discovery Collaboration
Evotec AG (Frankfurt Stock Exchange: EVT; NASDAQ: EVTC) today announced the start of a research collaboration with Novartis to identify and develop novel small molecule therapeutics. The collaboration will run for an initial period of three years. Evotec will apply its powerful drug discovery platform in combination with its extensive disease biology expertise to advance a drug discovery program against a target nominated by Novartis through discovery into the clinic.
Source: www.medicalnewstoday.com

Cleveland Clinic Begins Public Disclosure Of Physician-Industry Relationships
Cleveland Clinic this week began publishing on its Web site complete disclosures of physicians' and researchers' business relationships and financial ties, the New York Times reports.
Source: www.medicalnewstoday.com

Bionovo Announces Development Plans For Menopausal Hot Flash Drug Candidate, Menerba (MF101), Following FDA Meetings
Bionovo, Inc. (Nasdaq: BNVI) announced that the FDA has reviewed the company's manufacturing and control process descriptions (CMC), and has provided guidance on how Bionovo can move forward with the development of Menerba (formerly named MF101) for menopausal hot flashes. "We have concluded three CMC discussions with the FDA, and are moving to address the Agency's recommendations for further development of Menerba.
Source: www.medicalnewstoday.com

Sucampo Pharmaceuticals Selected As A Finalist For Scrip Awards 2008 Pharma Company Of The Year - Small And Medium-Sized Enterprises Award
Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP), a leading international biopharmaceutical company, today announced that it has been selected as a finalist for the Scrip Awards 2008 Pharma Company of the Year -- Small and Medium-Sized Enterprises Award. The Scrip Awards recognize the superior business performance of global pharmaceutical and biotechnology companies as well as companies that contribute to the advancement of science and healthcare.
Source: www.medicalnewstoday.com

Absence Of 'Frank Talk' About HIV/AIDS Hurts Black Women In Washington, D.C., Opinion Piece Says
"If ever there was a case for unvarnished sex education in public schools, the ongoing AIDS epidemic in black America ought to be it," columnist Courtland Milloy writes in a Washington Post opinion piece, adding, "[H]ow can we teach [HIV prevention] if we can't talk frankly?" Milloy writes that he is "focusing on women and AIDS ...
Source: www.medicalnewstoday.com

Investigating Numbness, Pain Or Muscle Weakness? Guidelines Identify Best Tests For Neuropathy
New guidelines developed by the American Academy of Neurology find a combination of blood tests and other specialized assessments appear to be the most helpful tests for finding the cause of neuropathy. Also known as neuritis or distal symmetric polyneuropathy, this common nerve problem affects people of all ages. The guidelines are published in the December 3, 2008, online issue of Neurology®, the medical journal of the American Academy of Neurology.
Source: www.medicalnewstoday.com